Chugai Seiyaku Kabushiki Kaisha

Osaka Bioscience Institute

Maruha Corporation

Satoru Takeda

Hiroshi Oda

Yoshihiro Urade

Nobuyuki Sato

Kosuke Seiki

Naomi Eguchi

Yasuhiko Shiina

Mitsuo Okubo

Hiroo Maeda

First, to solve the problems of the present invention, the present inventors confirmed the presence of ovarian cancer antigen-specific T cells in the peripheral blood of ovarian cancer patients by using an experimental system that detects combinations of CD4 and IL-4 or IFN&#x3b3;. Next, using analogue peptides of the core protein MUC 16 of the ovarian cancer-associated antigen CA 125, the present inventors revealed that antigen-specific CD4-positive T cells are present at an average frequency of about 4% in the peripheral mononuclear cells of patients and healthy subjects. Then, the present inventors analyzed the epitope for T cells in the core protein MUC 16 of the ovarian cancer-associated antigen CA 125, and determined the amino acid sequence FTLNFTITN (SEQ ID NO: 1) to be a shorter epitope. The present inventors further discovered that the analogue peptide OVCA11: GHTAPGPLLVPFTLNFTITN (SEQ ID NO:11) is suitable for T cell activation.

Cancer-associated antigen analogue peptides and uses thereof

Provided are: a method for predicting the onset of pregnancy-induced hypertension (PIH) by precisely detecting abnormalities that occur before the onset of PIH (where such abnormalities have been impossible to detect by various conventional testing methods for PIH) while imposing less of a burden on a subject; a method for evaluating a fetus and placental functions in PIH; and a method for detecting PIH, which comprises measuring the level of human lipocalin-type prostaglandin D synthase (L-PGDS) in a body fluid sample collected from a subject.

Method for predicting pregnancy-induced hypertension

Growing community of inventors

Saitama, Japan

Satoru Takeda